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Introduction:Multiple cardiac ion channels are prone to block by pharmaceutical compounds, and this can have
large implications for cardiac safety. The effect of a compound on individual ion currents can nowbemeasured in
automated patch clamp screening assays. In-silico action potential models are proposed as oneway of predicting
the integrated compound effects on whole-cell electrophysiology, to provide an improved indication of
pro-arrhythmic risk.
Methods: We have developed open source software to run cardiac electrophysiology simulations to predict
the overall effect of compounds that block IKr, ICaL, INa, IKs, IK1 and Ito to varying degrees, using a choice of
mathematical electrophysiology models. To enable safety pharmacology teams to run and evaluate these
simulations easily, we have also developed an open source web portal interface to this simulator.
Results: The web portal can be found at https://chaste.cs.ox.ac.uk/ActionPotential. Users can enter details of
compound afﬁnities for ion channels in the form of IC50 or pIC50 values, run simulations, store the results for
later retrieval, view summary graphs of the results, and export data to a spreadsheet format.
Discussion: This web portal provides a simple interface to reference versions of mathematical models, and
well-tested state-of-the-art equation solvers. It provides safety teams easy access to the emerging technology
of cardiac electrophysiology simulations for use in the drug-discovery process.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The heart's pumping action is driven by the ﬂow of electrically
charged particles — ions— across the membrane of muscle cells. These
ionsﬂow through protein channels in the cell membrane, which change
conformation dependent on the voltage (electrical potential due to a
difference in charge) across themembrane. The change in conformation
makes the ion channels permeable, or not, to the ﬂow of ions between
the inside and outside of the cell. If a channel is permeable, then ions
passivelymove through the pore, driven by their concentration gradient
and the electrical potential gradient across themembrane. Different ion
channels have evolved to be selective to different ionic species (e.g.
Na+, K+, Ca2+, Cl−), and to carry these ionic currents with differing
time- and voltage-dependence. A number of pumps and exchangers
actively move ions back across the membrane to restore intra- and
extra-cellular concentrations of ions, enabling sustainable electrical
activity.
Ion channels can be blocked by pharmaceutical compounds due to
their binding directly to channel pores, or compound binding can lead
to conformational changes of the ion channel and also lead to impaired
passage of ions. Some cardiac ion channels, such as hERG channels, ares).
. Mirams).
. This is an open access article underparticularly prone to block, by a wide variety of pharmaceutical com-
pounds (Mitcheson & Perry, 2003). Blockade of the hERG potassium
channel is linked with prolongation of electrical activity at the cell,
organ, and body-surface (observed as an increase in the QT interval of
the ECG). Both block of hERG and prolongation of QT interval are linked
with pro-arrhythmic Torsade-de-Pointes risk (Redfern et al., 2003;
Sanguinetti & Tristani-Firouzi, 2006; Pollard et al., 2010). As such,
hERG block and human QT intervals are assessed as part of the ICH-
S7B and ICH-E14 safety guidelines (ICH, 2005a, 2005b).
Improved predictions of torsadogenic risk have been created using
information on a compound's interactions with not simply hERG, but
also additional ion channels (Mirams et al., 2011; Kramer et al., 2013).
In early drug discovery, compounds are commonly screened for their ef-
fect on particular cardiac ion currents using cell lines that over-express
certain genes. Table 1 shows common choices for human ventricular
targets that routinely feature in pharmaceutical safety screens.
Directmeasurements of the overall action of a compound are provid-
ed in later safety testing on isolatedmyocytes, tissue cultures, or ex-vivo
cardiac tissue preparations. It would be beneﬁcial to be able to provide
these ‘integrated’ predictions for larger numbers of compounds, earlier
in drug discovery, prior to such experiments being performed. One
way to do this is to let biophysical mathematical models integrate any
multi-channel effects of a compound, based on channel screening data.
The targets shown in Table 1 were chosen as potential inputs for
simulations because they (i) are important in controlling cardiacthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Assumptions of the cardiac currents that are recorded from cell lines expressing certain
genes. Each of these can be given an IC50 value in web portal simulations, which is then
used to calculate conductance-block in action potential simulations.
Gene Protein Current Current description
hERG or KCNH2 Kv11.1 IKr Rapid delayed rectifying potassium current
CACNA1C Cav1.2 ICaL L[ong-lasting]-type calcium current
SCN5A Nav1.5 INa [Fast] sodium current
KCNQ1/minK Kv7.1 IKs Slow delayed rectifying potassium current
KCNJ2 Kir2.1 IK1 Inward rectiﬁer potassium current
KCND3 Kv4.3 Ito,fast Fast transient outward potassium current
If a model only contains total Ito then this is conductance blocked instead of Ito,fast.
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compounds, and (iii) are possible to screen with automated assays.
Additional ion currents can, of course, also be affected by com-
pounds. The late/persistent sodium current INaL is of particular interest,
as it has been affected by a number of pharmaceutical compounds, and
modelling work on block this current has been performed (Noble &
Noble, 2006; Moreno et al., 2013). The story is complicated by the fact
that late sodium represents just part of the overall sodium current,
which may emerge from channel kinetics, or may be carried by voltage-
gated sodium channels other than Nav1.5 (Noujaim et al., 2012; Yang
et al., 2012). Late sodium does not yet have a standard representation in
the mathematical models: sometimes it is a separate current; sometimes
late sodium is modelled by preventing inactivation of fast sodium; and
sometimes late sodium is represented as a distinct conducting state in a
Markov model of the Nav1.5 channel (Irvine, Jafri, & Winslow, 1999).
For this reason, introducing late sodium current block into the literature
action potential models is not straightforward, and is future work.
The FDA, Cardiac Safety Research Consortium, Health and Environ-
mental Sciences Institute and Safety Pharmacology Society are working
on a new Comprehensive in-Vitro Pro-arrhythmia Assay (CiPA). The
CiPA initiative intends to use mathematical (in-silico) action potential
models to integrate multiple ion channel screening data and to make
predictions about pro-arrhythmic risk, to be compared with stem-cell
derived myocyte assays (Sager, Gintant, Turner, Pettit, & Stockbridge,
2014). As suggested by some commentaries, the computational models
need thorough testing, standardisation and wide availability for such
uses (Gintant, 2012; Kleiman, Shah, & Morganroth, 2014; Cavero &
Holzgrefe, 2014). To this end, this article introduces a publicly accessible
open-source web portal we call ‘AP predict online’. The portal has been
developed to enable electrophysiology simulations to be performed by
safety teams, to evaluate the performance of different models and to
deﬁne suitable contexts of use.
2. Methods
2.1. Mathematical electrophysiology models
Mathematicalmodels of cardiac electrophysiology offer away to inte-
grate the effect of blocking individual types of cardiac ion current, in order
to predict effects at the whole-cell level, and higher. The models are
designed to describe the evolution of the cell's electrical activity due to
the interaction of the different ionic currents. The electrical activity is
most commonly described by the action potential — the activation and
recovery (known as de- and re-polarisation) of transmembrane voltage.
The models therefore describe the evolution of membrane voltage
through time by modelling the membrane as simply a capacitor, and
saying “the change in voltage is proportional to the sum of the ionic
currents across the membrane”. This is expressed quantitatively as an
ordinary differential equation:
dV
dt
¼− 1
Cm
X
channelsj
I j þ Istim
0
@
1
A: ð1ÞHere V is the transmembrane voltage, t is time, Cm is the capacitance
of the membrane, Ij represents each type of ionic current j, and Istim is
any stimulus current applied to the cell. This can become a complicated
system of nonlinear equationswhenwe consider that the ionic currents
Ij are themselves nonlinear functions of both voltage and time.
This forms a nonlinear system where intuition often fails us, and so
quantitative models have allowed much progress, beginning with the
Nobel prize winningwork of Hodgkin and Huxley (1952), and its appli-
cation to cardiac cells by Noble (1960). Many of the large advances
since — discoveries of new currents, and uncovering of the roles of
ionic currents in arrhythmia mechanisms — have been enabled by
these mathematical modelling efforts (Noble & Rudy, 1783). Modern
mathematical models now include all of themajor cardiac ion channels,
pumps and exchangers, as well as a detailed description of the calcium
subsystem, and the concentration of ions in different cellular compart-
ments. As an example of a modern model, the currents that are
modelled in the Shannon,Wang, Puglisi, Weber, and Bers (2004) rabbit
ventricle model, available for AP-predict simulations, are shown in
Fig. 1.
The AP-predict web portal provides an interface to a simulation tool
that attempts to predict changes to the cellular action potential, given
the data we have already obtained from cardiac ion channel screens in
Table 1. At present the followingmodels are available from theweb por-
tal: rabbit— Shannon et al. (2004), Mahajan et al. (2008); human— Ten
Tusscher and Panﬁlov (2006), Grandi, Pasqualini, and Bers (2010),
O'Hara, Virág, Varró, and Rudy (2011); and human stem-cell derived
myocyte (Paci, Hyttinen, Aalto-Setälä, & Severi, 2013). These models
have been chosen to represent the assays that are commonly performed
and of safety interest, and to include some of themodels that have been
used to simulate pharmaceutical compound block in the literature
(discussed in Section 3). Any further models that are in the Physiome
Model Repository could be added easily to future versions of the portal,
and the authors will be pleased to assist with this.
2.2. Data for model input
AP-predict uses simple concentration–response curves to determine
the degree of reduction to be applied to each channel's maximal
conductance, for any given concentration. The simulations integrate
the concentration–effect curves from multiple ion channel screens (for
any channel listed in Table 1), to predict the effect on the whole cell
level, as shown in Fig. 2.
A concentration–response (or concentration–effect) curve is
commonly deﬁned as:
% current remaining ¼ 100%
1þ Conc:½ IC50½ 
 Hill : ð2Þ
Eq. (2), plotted in Fig. 3A, provides a very accurate description of
(peak) ion-current blockade for most compounds. In the (Elkins et al.,
2013) study, we found large variability was associated with Hill coefﬁ-
cient measurements from high-throughput screens. We believe this
variability is likely to be a larger source of error than simply saying
that “the Hill coefﬁcient is equal to one” in most cases (as from ﬁrst
principles, Hill = 1 occurs when one compound interacts with one ion
channel and a channel can be fully blocked by a single molecule of the
compound).
Our concentration–response curve is therefore fully deﬁned by a
single IC50 value — that is, the concentration of the compound that
would inhibit the maximum current by 50%. The web portal should be
provided with IC50 (or pIC50) values that result from data ﬁtted to this
curve, as shown in Fig. 3B. Where an IC50 is not directly observed (e.g.
you only know that IC50 b 30 μM, since at 30 μM 50% block was
not achieved), you should still input the ‘extrapolated’ IC50 that
parameterises the concentration–response curve ﬁtted through the
Fig. 1. Currents included in the (Shannon et al., 2004) rabbit ventricle model. Ionic pumps are represented by yellow circles, and exchangers by blue circles, the rest of the components in
the membrane are ion channels. Currents are given their usual abbreviations, as shown in Table 1. Image adapted from the Physiome Repository http://bit.ly/1J9Z9UI.
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default action is that no block is applied to that channel.
In terms of assay choice, manual whole-cell patch voltage clamp
data remains the gold standard and would therefore be the best option
(as used in the Mirams et al. (2011) Torsade risk prediction study).
Where these data are not available, in earlier drug discovery perhaps,
we have also examined using data from high-throughput automated
patch clamp screens, as discussed in Section 3.
2.3. Assumptions
The following quotation from James Black is a perfect summary of
the role of mathematical models in this context.
“[Mathematical] models in analytical pharmacology are not meant
to be descriptions, pathetic descriptions, of nature; they are
designed to be accurate descriptions of our pathetic thinking about
nature. They are meant to expose assumptions, deﬁne expectations
and help us to devise new tests.”
Black (1989)
So in-silico action potential models should not be thought of as
performing a simulation that says “this will be the result of a later exper-
iment”. Rather they provide away to deﬁne our expectations: “this is the
effect you would expect to see in a later experiment if the compound blocksFig. 2. Inputs and outputs of the action potential simulations. Left: ion current concentration–eff
of block at any given concentration. The percentage block is applied to each current in amathem
time limit), and calculate the action potential and examine its duration. The process is repeatecardiac ion channels as detected by the early ion-channel screens, and the
electrophysiology of the cell works the way we think it does”. The act of
modelling therefore forces us to be explicit about our assumptions and
approximations in the safety testing and modelling processes, which
we examine further below.
Wehave only considered the compound's action on the screened ion
channels. Clearly, if the compound affects other channels, the integrated
response will not be predicted accurately. In addition, chronic changes
to an ion current (due to changes in trafﬁcking or other regulation of
ion channel expression and/or function) are not captured in the data
providing inputs into the simulations.
Each IC50 that is used is assumed to be accurate. But we know that
the high-throughput automated platforms in particular have some lim-
itations: many operate at room temperature rather than physiological
temperatures; and many compounds can bind to the plastics used in
piping andwells,which lowers the effective concentration that is tested.
As discussed earlier, there is also signiﬁcant variability associated with
IC50 values from many of these screens (Elkins et al., 2013).
We have assumed ‘conductance block’ of ion currents. That is, the
compound does not preferentially bind to the ion channel in any partic-
ular conformation. Certain compounds break this assumption, when
binding has a dependence on channel state and/or membrane voltage.
This is one mechanism by which ‘use [pacing rate]-dependent’ block
can arise. Additionally, we are assuming that a compound does not
affect the ion current's voltage-dependent behaviour (rates of kineticect curves are taken from each high throughput screen (HTS) and used to calculate a degree
atical model ventricular electrophysiology.We then simulate steady pacing (up to a given
d for a range of concentrations, and the results are plotted in a summary graph.
Fig. 3. Use of IC50 values to parameterise concentration–effect curves. A: plot of the concentration–response curve given by Eq. (2) with Hill = 1; note that 50% block occurs when
[Concentration] ÷ [IC50] = 1. B: a curve ﬁtted to data spanning the effect range. C: a curve ﬁtted to data that are all below 50% inhibition.
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only considers antagonistic blockade and reduction of the ion channel
currents, agonist action is also possible (but rarer), and could be included
in future versions.
Simulations apply the steady-state level of block instantaneously,
we do not model the accumulation of the compound in the tissue, or
the time-dependence of its binding to ion channels. Note that the
simulation still has to be run for a large number of paces, as instant
steady-state block of channels will not lead to instant steady-state
changes in the resulting action potential model (this slow adaptation
of the action potential to interventions is also observed in experiments).
We are predicting the percentage change in single-cell action poten-
tial duration,we typically infer that the change in ventricularQT interval
on an ECG should be similar. Early tissue simulation work shows that
there is an excellent correspondence between the two, but QT effects
may be slightly larger than action potential changes on average.1
The ion channels that were screened in over-expression systems
were human isoforms, not animal proteins that can often be found in
later safety tests. So, if anything, on this point we might expect to be
able to provide better simulation predictions in the human rather than
animal situation.
2.4. Technical implementation
The underlying simulation software (‘AP predict’) and the web
portal (‘AP-predict online’) are released as open source software
under the BSD 3-clause licence.2
2.4.1. Simulation software
The action potential prediction software ‘APpredict’ is a bolt-on C++
project to the open-source and well-tested ‘Chaste’ computational
biology library (Mirams et al., 2013; Pathmanathan & Gray, 2013),
both are available to download via https://chaste.cs.ox.ac.uk/trac/wiki/
ApPredict.
A brief discussion of the steps involved within AP predict follows.
The Physiome Model Repository3 contains machine-readable descrip-
tions of each model's equations in CellML format (Lloyd, Lawson,
Hunter, & Nielsen, 2008), and ‘AP predict’ is shipped with a copy of
some of these CellML ﬁles. PyCML is used to convert CellML model
representations into Chaste C++ ﬁles (Cooper, Corrias, Gavaghan, &
Noble, 2011). ‘CVODE’ is then used to solve the differential equations1 see an informal blog entry on this: http://mirams.wordpress.com/2014/03/21/apd_
vs_qt/ for more information.
2 http://opensource.org/licenses/BSD-3-Clause.
3 https://models.physiomeproject.org/electrophysiology.(Hindmarsh et al., 2005),with variable-order BackwardsDifferentiation
Formulae solvers, taking adaptive time steps, with settings for absolute
and relative tolerances of 10−6 and 10−8 respectively. This solver
showed the best performance for cardiac electrophysiology amongst
the suite of Chaste differential equation solvers in a recent benchmark
study (Cooper, Spiteri, & Mirams, 2014). We simulate multiple paces,
until a pseudo-steady response to the requested frequency has emerged
(i.e. the same behaviour on subsequent paces). This steady state is
deﬁned as when the Euclidean (L2) norm of the vector of ODE state
variable changes between paces is less than 10−6. Output is requested
every 0.1 ms for the steady-state pacing action potential waveform
(dictating the accuracy of action potential duration calculations), and
the output is then down-sampled for fast visual presentation in the
web portal.
2.4.2. Web portal
The ‘AP-predict online’web portal is also free open source software.4
The portal has three principal components: the ‘client-direct’ compo-
nent which stores simulation results and generates HTML for rendering
the portal web page in a web browser; the ‘app-manager’ component
which invokes the ‘AP predict’ simulation software and monitors simu-
lation progress; and ﬁnally the ‘AP predict’ simulation software itself
(discussed above). The client-direct and app-manager software are
written in the ubiquitous Java language as Java servlets, and make
extensive use of the popular Spring Framework.
The client-direct and the app-manager components communicate
via web services; the beneﬁt of this is that the two components do
not need to be running on the same machine. As each simulation is
compute-intensive and may take up to ten minutes to complete, the
option to spread the work means that the portal page can remain
responsive whilst simulations take place.
2.5. Security and privacy
Users can register for free on the public portal running on Oxford
servers at https://chaste.cs.ox.ac.uk/ActionPotential, via the ‘Registra-
tion Form’ button on the portal homepage. A user name and password
for log in will then be sent to the user by e-mail. Once logged in, the
portal ensures your simulation inputs and results are accessible to you
alone. Whilst we do not intend to analyse the information that is
entered, information is necessarily stored in a database on the Oxford
server to allow you to view results and revisit past simulations, and
this database is accessible to the software development team. The portal4 Available from https://bitbucket.org/gef_work/ap_predict_online.
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mation being intercepted between your web browser and the Oxford
servers.
Wewould still strongly recommend that sensitive proprietary infor-
mation is not entered into the public portal, in case of the unlikely event
that this server is compromised. However, since the portal itself is open
source software, one could set up a private copy of the portal inside a
ﬁrewall on an intranet, which some industrial users may wish to do
for increased data security. In future we will be releasing additional
template code that, when conﬁgured, will allow ﬁre-walled copies of
the portal to query internal databases of IC50 results, after further trials
of this with pharmaceutical partners.
3. Results
The web portal provides a simple interface to simulation results, for
each user to retrieve easily at a later date. An example of the web portal
results page can be seen in Fig. 4. All of the results that are displayed can
be exported in a spreadsheet ﬁle format.
Should the results exhibit unusual action potential behaviour such as
alternans, or failure to de/re-polarise, then the user's attention is drawn
to this via an additional ‘messages’ button next to the results.
A number of evaluations have been performed of the web portal
predictions. InMirams et al. (2011) we showed an excellent correlation
between clinical torsadogenic risk and APD90 predictions from the
Grandi et al. (2010) model, based on (manual) patch-clamp hERG,
CaV1.2 and NaV1.5 IC50 data, when simulating the compound effect at
clinical maximum effective free plasma concentrations.
In a more thorough evaluation of direct portal predictions, we ran
predictions of the GlaxoSmithKline rabbit wedge assay for a large num-
ber of proprietary compounds (Beattie et al., 2013). We examined
whether a compound caused over 10% QT prolongation (or shortening)
at any of the concentrations at which it was tested, and then comparedFig. 4. A screen shot of the web portal presentation of simulation results. On the left is a summa
concentration ranges. On the right is a summary plot of percentage changes to APD 90, and a pwhether or not the APD90 simulation result, based on screening
data, showed the same. Simulations based on medium-throughput
PatchXpress screens reached 75% accuracy at predicting this prolongation
in the rabbit wedge.
We considered how to measure and account for uncertainty in ion
channel screening in Elkins et al. (2013), that study provides a method
for determining the subsequent uncertainty in simulation predictions.
These simulation conﬁdence intervals will be added to the AP-predict
web portal where possible in future versions.
In Mirams et al. (2014) we have compared APD90 predictions from
three human models (all available in the portal) with the results of
human clinical Thorough QT studies. There is a good correspondence,
although simulations tended to underestimate the effect that was
observed at the estimated clinical free drug concentration. We suspect
this could be due to uncertainty in free drug concentration, since similar
simulations estimated the concentration at which 10% prolongation
occurred much more accurately in the ex-vivo rabbit wedge study
discussed above, see Beattie et al. (Fig. 2, 2013).
4. Discussion
There are two main contexts of use in which the portal may be
helpful: as soon as ion channel screens have been performed; and
later when isolated myocyte or tissue-based experiments have been
performed. We will discuss these cases separately below.
4.1. Before further experiments
Theportal can be used to put together the information froma cardiac
ion channel screening panel and deﬁne expectations of the likely total
effect, in different situations. For example predictions can be made for
different pacing rates (even though the IC50 does not capture use depen-
dence, differences in the contribution of currents at different pacingry of the inputs into the simulations: the model; pacing details; channel pIC 50 values; and
lot of the steady-state action potential at each test concentration.
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made for different species or cell types. In the context of the CiPA effort,
the means we can make predictions for both stem-cell derived
myocytes and adult myocytes. Where it is not feasible to progress all
compounds to further experiments, results of the simulations can be
used to rank compounds in terms of potential QT liability. The portal
predictions are also helpful in designing further experiments by
selecting the most likely compound concentrations for observable
effects.
4.2. After further experiments
At this time, we believe electrophysiology models may bemost use-
ful in the context of further experiments, particularly stem-cell derived
myocyte assays in the new CiPA paradigm. We discuss the conse-
quences of agreement or disagreement with further experiments
below.
4.2.1. Agreement
If the AP-predict prediction is strongly aligned with the further
experimental results (in animal tissue or stem-cell derived myocytes
for example), this provides strong evidence that we know the likely
APD/QT effects, and we also know why they occur. That is, we know
howmuch the compound blocks particular ion channels, andwe under-
stand mechanistically and quantitatively how this leads to APD/QT
changes. This provides us with an increased degree of conﬁdence in
predicting any clinical effect in human, especially via simulation of the
adult human ventricular response.
4.2.2. Disagreement
A large disagreement between simulation and experiment is likely
to indicate additional compound effects that have not been captured
by the ion channel screens. When comparing simulations at the single
cell level with tissue experiments it is important to remember that
tissue-level effects, such as blockade of gap junctions between cells
could also be playing a role, but this should generally be detected via
QRS widening or similar measures of conduction velocity. Most
disagreements between simulation predictions and experimental
results probably mean that one of the assumptions/approximations
listed in Section 2.3 has been violated.
An alternative explanation is that the mathematical model that is
used is not capturing the interaction of the currents thatmakeup the ac-
tion potential properly.We cannot yet rule this out, andwork is ongoing
to improve the model(s). We would suggest that thorough evaluations
be performed with each model for each ‘context of use’. For example,
this ‘model error’ is thought to be a small effect when predicting rabbit
wedge results with the Shannonmodel, due to the excellent correspon-
dence between simulation and experiment for over 50% of the N 100
compounds we have evaluated to date with GSK (Beattie et al., 2013).
4.3. Future work
The web portal is a simpliﬁed version of a more fully-featured and
database-integrated portal which remains under development. We are
in the process of incorporating uncertainty in IC50 inputs into the web
portal, to provide a conﬁdence interval on predictions. This requires a
large number of repeated experiments for one compound on each spe-
ciﬁc screening assay, the portal will need to include a new calibration
step to analyse the spread of such data.
An important task at present is to assess themost predictive in-silico
pro-arrhythmic risk markers, other than simply action potential
duration. This is an active area of our research. A discussion of possible
metrics was given at a recent CiPA update meeting (Mirams, 2015). As
new markers of clinical pro-arrhythmic risk become available, we willadapt the portal to perform these simulations and provide an indication
of pro-arrhythmic risk alongside the predicted action potentials.
We plan towork on the problem of capturing detailed kinetics of ion
channel block in mathematical models of compound action. The math-
ematical modelling community will need to work with cardiac safety
teams to establish the best voltage protocols to measure such details,
and to standardise the model representations for automated inclusion
in action potential model predictions.4.4. Summary
In summary, there is strong evidence that simulations of the effect of
ion channel block on cellular action potential can provide valuable
insight on the combined multiple ion-channel action of a novel
compound, and subsequent consequences for its cardiac safety. The
web portal that we have presented here allows such simulations to be
performed freely and easily.Acknowledgements
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